Trials in California.
139 APOE4-relevant Alzheimer’s trials run in California — 74 of them recruiting. Each one translated into plain English, with our read on what it means for an APOE4 carrier.
- Carriers enrolled, but higher ARIA riskNCT01767311A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease
This Phase 2 trial tested lecanemab, an anti-amyloid antibody given by infusion, in people with early Alzheimer's disease — either mild cognitive impairment or…
- Built exclusively for APOE 4/4 carriersNCT02565511A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested two investigational drugs, CAD106 (a vaccine-like immunotherapy targeting amyloid) and CNP520 (a small molecule targeting amyloid…
- Built specifically for APOE4 carriersNCT03131453A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested CNP520, a drug designed to reduce amyloid buildup in the brain, against a placebo in cognitively normal older adults at elevated risk for…
- Open to carriers, but ARIA risk elevatedNCT03887455A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
This Phase 3 trial tests lecanemab, an intravenous and subcutaneous antibody drug, against placebo in people with early Alzheimer's disease — either mild…
- APOE4 carriers explicitly welcomedNCT04468659AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
This Phase 3 trial is testing lecanemab, an anti-amyloid antibody drug, in people who are cognitively normal but have early amyloid buildup in their brains —…
- Built exclusively for APOE4/4 carriersNCT04770220An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
This Phase 3 trial is testing ALZ-801, an oral drug designed to reduce toxic amyloid clusters in the brain, against a placebo in people with early Alzheimer's…
- APOE4/4 only, closed to new enrolleesNCT06304883Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects
This is a long-term extension of a Phase 3 trial testing ALZ-801, an oral drug designed to reduce toxic amyloid clumps in the brain. Researchers are tracking…
- Exclusively recruits APOE4 carriersNCT07288463Hearing Loss and Genetic Risks for Alzheimer's Disease and Related Dementia
This pilot study is testing whether over-the-counter hearing aids are practical and acceptable for older adults at high risk for dementia who have…
- Exclusively recruits APOE4 carriersNCT07516119Predicting Pre-dementia
This observational study is testing whether a multimodal prediction model — combining genetic risk scores, blood biomarkers, health record data, and wearable…
- Exclusively recruits APOE4 carriersNCT07646054Digital Lifestyle Coaching for Alzheimer's Disease Prevention in APOE4 Carriers
This trial is testing whether a year-long digital lifestyle coaching program can improve blood-based markers linked to Alzheimer's risk. Twelve hundred…
- General AD trial, no APOE4 focusNCT00265148Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease
This Phase 2 trial tested rosiglitazone, a drug originally developed for type 2 diabetes, against a placebo in people with mild to moderate Alzheimer's…
- APOE4 enrolled, response may differNCT00348140Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease
This Phase 3 trial tested rosiglitazone, a diabetes drug, as an add-on to standard Alzheimer's medications like Aricept in people with mild to moderate…
- Enrolled carriers, prior data unfavorableNCT00348309Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease
This trial tested whether rosiglitazone extended release, a diabetes drug, could improve thinking and memory in people already taking donepezil for mild to…
- APOE4 stratified, suggests less benefitNCT00428090Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease
This Phase 3 trial tested rosiglitazone XR, a diabetes drug already approved for type 2 diabetes, as a standalone treatment for mild to moderate Alzheimer's…
- Closed trial, APOE4 stratifiedNCT00550420Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers
This Phase 3 trial tested rosiglitazone XR, a diabetes drug, in people with mild-to-moderate Alzheimer's disease. It was an open-label extension study, meaning…
- Open to carriers, not 4-specificNCT00710684A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease
This trial tested SB-742457, an experimental drug added on top of donepezil, the standard Alzheimer's medication, in people with mild-to-moderate Alzheimer's…
- Amyloid-focused, drug did not succeedNCT02008357Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
This Phase 3 trial tested solanezumab, an antibody drug given by IV infusion, in cognitively normal older adults who already had amyloid buildup in their…
- Open to carriers, not 4-specificNCT02245737An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
This trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, against a placebo over two years in people with early…
- Open to carriers, not 4-specificNCT02814526Exercise in Adults With Mild Memory Problems
This trial tests whether aerobic exercise (like treadmill walking) does more for brain health than stretching and balance routines in older adults with mild…
- Heart trial, genotype not relevantNCT02884206Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction
This Phase 3 trial tested whether LCZ696 (sacubitril/valsartan, sold as Entresto) protects cognitive function better than valsartan alone in people with a…
- Observational only, no treatment involvedNCT02951598A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)
This study is not testing a treatment. It is an observational study tracking how people with early-stage Alzheimer's disease or MCI use health care, what that…
- Discontinued trial, not APOE4-specificNCT02972658A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia
This Phase 3 trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, in people with early Alzheimer's dementia. It…
- Cancer patients only, genotype not specifiedNCT03016741Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
This trial is studying whether prostate cancer hormone therapies — specifically abiraterone acetate and enzalutamide — affect brain structure and cognitive…
- Unrelated to APOE4 or Alzheimer'sNCT03047369The Myelin Disorders Biorepository Project
This is a biorepository project, not a treatment trial. Researchers are collecting medical records and biological samples (like blood or tissue) from people…
- Open to carriers, not 4-specificNCT03108846Escitalopram for Agitation in Alzheimer's Disease
This Phase 3 trial is testing whether escitalopram, a common antidepressant, can safely reduce agitation in people who already have Alzheimer's dementia. Phase…
- Open to carriers, not 4-specificNCT03507257Longitudinal Early-onset Alzheimer's Disease Study Protocol
LEADS is an observational study, not a treatment trial. Researchers are tracking how early-onset Alzheimer's and related conditions progress over time in…
- Designed specifically around APOE4 carriersNCT03613844DHA Brain Delivery Trial
This trial is testing whether APOE4 carriers absorb less DHA (an omega-3 fatty acid) into the brain compared to non-carriers, and whether DHA supplements can…
- Open registry, genotype not requiredNCT03638583Alzheimer Prevention Trials (APT) Webstudy
The APT Webstudy is not a treatment trial. It is an online registry that tracks cognitive health over time in people 50 and older who do not have dementia. The…
- Open to carriers, not 4-specificNCT03703856Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease
This trial is testing memantine, an FDA-approved Alzheimer's medication, to understand which patients respond to it best by tracking brain function and symptom…
- Open to carriers, genotype not requiredNCT03860857Biomarker Exploration in Aging, Cognition and Neurodegeneration
This observational study is tracking brain changes in people 60 and older who currently have normal cognition. Researchers are using MRI, amyloid PET, tau PET,…
- Open to carriers, not 4-specificNCT03881579Supportive Care for Cognitively Impaired Patients and Families
This trial tests whether a year-long nurse-led palliative care program improves quality of life and reduces healthcare use for people living with dementia or…
- Not APOE4-related, movement disorder focusNCT03924414Trial of Parkinson's And Zoledronic Acid
This trial is testing whether a single IV infusion of zoledronic acid, a bone-strengthening drug already approved for osteoporosis, can reduce fractures in…
- Open to carriers, genotype not trackedNCT04098666Metformin in Alzheimer's Dementia Prevention
This trial is testing whether extended-release metformin, a widely used diabetes drug, can slow memory decline in people who are overweight and already showing…
- Open to carriers, genotype not requiredNCT04100057Sleep Disturbance and Emotion Regulation Brain Dysfunction as Mechanisms of Neuropsychiatric Symptoms in Alzheimer's Dementia
This trial tests whether treating insomnia with Cognitive Behavioral Therapy for Insomnia (CBT-I) reduces anxiety, depression, agitation, and other behavioral…
- Lifestyle study, genotype not requiredNCT04141878Dementia and Diabetes Prevention Program
This trial is testing two lifestyle changes — aerobic exercise and a brain-healthy diet called the MIND diet — to see whether they reduce the risk of cognitive…
- Open to carriers, not 4-specificNCT04148391NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)
This trial is testing NYX-458, an experimental oral drug, against a placebo in people who have mild cognitive impairment or mild dementia caused by Parkinson's…
- Not relevant to APOE4 carriersNCT04165109Trial-Ready Cohort-Down Syndrome (TRC-DS)
This is not a treatment trial. It is a study building a pool of adults with Down syndrome, ages 25 to 55, who are ready to be recruited into future Alzheimer's…
- Open to carriers, genotype not trackedNCT04171323The Active Mind Trial: An Adaptive Randomized Trial to Improve Function and Delay Dementia
This trial is testing different combinations of computerized brain exercises to see which combination best helps older adults with mild cognitive impairment…
- Open to carriers, not 4-specificNCT04262206Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
PREVENTABLE is a large Phase 4 trial testing whether atorvastatin 40 mg — a common cholesterol-lowering statin — can reduce the combined risk of death,…
- Open to carriers, genotype not requiredNCT04296565Water-based Activity to Enhance Recall in Veterans
This trial tests whether combining water-based exercise with a cognitive training program improves memory in veterans who have amnestic Mild Cognitive…
- FTLD-focused, not APOE4-relevantNCT04363684ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
This is a large North American research registry and natural history study tracking people with frontotemporal lobar degeneration (FTLD) and related conditions…
- High ARIA risk for carriersNCT04437511A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
This Phase 3 trial tested donanemab, an anti-amyloid antibody drug, against placebo in people with early Alzheimer's disease. Researchers measured how well it…
- Open to carriers, not 4-specificNCT04500847Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD
This trial is testing emtricitabine — an HIV antiviral drug — as a possible intervention for people who already have biomarker-confirmed MCI or mild to…
- Open to carriers, not 4-specificNCT04558164Network-targeted Theta-burst Stimulation for Episodic Memory Improvement in Mild Cognitive Impairment
This trial is testing whether a non-invasive brain stimulation technique called transcranial magnetic stimulation (TMS) can improve memory in people with mild…
- Open to carriers, genotype not requiredNCT04566900Neurofeedback to Improve Working Memory in Mild Cognitive Impairment
This trial is testing whether neurofeedback — a technique that trains people to consciously shift their own brain activity using real-time visual or audio…
- Vague scope, genotype not consideredNCT04684602Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions
This Phase 1 trial is testing whether mesenchymal stem cell therapy — delivered as products called PrimePro and PrimeMSK — is safe and tolerable across a wide…
- Genotype-neutral diagnostic tool studyNCT04800588Computerized Tests of Cognitive Decline in Presymptomatic Alzheimer's Disease
This trial is testing a new set of computerized cognitive assessments called the California Cognitive Assessment Battery. Researchers want to establish normal…
- Open to carriers, not 4-specificNCT04838301Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease
This trial is testing allopregnanolone — a naturally occurring brain steroid — to see whether it slows or improves cognition in people with mild Alzheimer's…
- Not relevant to APOE4 riskNCT04881617Treatment for Speech and Language in Primary Progressive Aphasia
This trial is testing two speech-language therapies for people with primary progressive aphasia, a neurological condition that slowly erodes the ability to…
- Caregiver study, genotype irrelevantNCT04894006Dementia Family Caregiver Study
This trial tests a 3-month home visit program delivered by community health workers to family caregivers of people with dementia. Caregivers wear a smartwatch…
Copy a forum-ready post
Keep exploring
Educational, not medical advice. Trial decisions belong between you and your physician.